CA
UTHR icon

Continuum Advisory’s United Therapeutics UTHR Stock Holding History

Continuum Advisory’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$112K Buy
+207
New +$117K 0.01% 616
2025
Q2 		– Sell
-11
Closed -$3.39K – 1518
2025
Q1 		$3.39K Sell
11
-3
-21% -$1.03K ﹤0.01% 1196
2024
Q4 		$4.94K Sell
14
-4
-22% -$1.47K ﹤0.01% 1140
2024
Q3 		$6.95K Buy
18
+13
+260% +$4.39K ﹤0.01% 1083
2024
Q2 		$1.59K Sell
5
-3
-38% -$794 ﹤0.01% 1353
2024
Q1 		$2.13K Buy
+8
New +$1.8K ﹤0.01% 1282

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Continuum Advisory's UTHR Position: Q2 2026 in Review

Continuum Advisory opened a new position in United Therapeutics (UTHR) in Q2 2026: 207 shares worth $112K. The stake represents 0.01% of the portfolio and ranks #616 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in UTHR as recently as Q1 2025.

Continuum Advisory first reported a position in UTHR in Q1 2024 and has held it in 6 quarters since. 882 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Continuum Advisory held 207 shares of United Therapeutics worth $112K as of Q2 2026.
  • United Therapeutics was a new Continuum Advisory position in Q2 2026.
  • United Therapeutics made up 0.01% of Continuum Advisory's portfolio in Q2 2026, its #616 holding.
  • Continuum Advisory first reported a position in United Therapeutics in Q1 2024 and has held it in 6 quarters since.
  • 882 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.